Insights
What is actually changing in this market — pricing, clinical practice, and how vendors are being bought. No vendor bylines, no sponsored posts.
PricingJuly 19, 2026· 7 min read
The compounded GLP-1 cliff and what it did to vendor pricing
When compounded semaglutide access narrowed, the vendors built on it had to re-price. Here is who absorbed it and who passed it through.
ClinicalJuly 12, 2026
Persistence, not weight loss, is the metric that decides your ROI
Every vendor leads with average weight reduction. The number that actually determines whether your spend produced anything is how many members are still on therapy at month twelve.
9 min
ClinicalJune 30, 2026
The lean mass problem is becoming a contracting issue
Body composition during rapid weight loss has moved from a clinical footnote to something buyers are starting to write into agreements.
8 min
MarketJune 22, 2026
Point solution fatigue is reshaping how GLP-1 vendors get bought
Benefits teams running a dozen vendors are consolidating. That changes which GLP-1 vendors win, and it is not always the best clinical one.
6 min